ALLEGRA D-12 HOUR- fexofenadine hydrochloride and pseudoephedrine hydrochloride tablet, extended release USA - engelsk - NLM (National Library of Medicine)

allegra d-12 hour- fexofenadine hydrochloride and pseudoephedrine hydrochloride tablet, extended release

physicians total care, inc. - fexofenadine hydrochloride (unii: 2s068b75zu) (fexofenadine - unii:e6582loh6v), pseudoephedrine hydrochloride (unii: 6v9v2ryj8n) (pseudoephedrine - unii:7cuc9ddi9f) - fexofenadine hydrochloride 60 mg - allegra-d 12 hour extended-release tablets are indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children 12 years of age and older. symptoms treated effectively include sneezing, rhinorrhea, itchy nose/palate/ and/or throat, itchy/watery/red eyes, and nasal congestion. allegra-d 12 hour should be administered when both the antihistaminic properties of fexofenadine hydrochloride and the nasal decongestant properties of pseudoephedrine hydrochloride are desired (see clinical pharmacology). allegra-d 12 hour is contraindicated in patients with known hypersensitivity to any of its ingredients. due to its pseudoephedrine component, allegra-d 12 hour is contraindicated in patients with narrow-angle glaucoma or urinary retention, and in patients receiving monoamine oxidase (mao) inhibitor therapy or within fourteen (14) days of stopping such treatment (see drug interactions section). it is also contraindicated in patients with severe hypertension, or severe coronary arter

ALLEGRA-D 24 HOUR- fexofenadine hydrochloride and pseudoephedrine hydrochloride tablet, film coated USA - engelsk - NLM (National Library of Medicine)

allegra-d 24 hour- fexofenadine hydrochloride and pseudoephedrine hydrochloride tablet, film coated

stat rx usa llc - fexofenadine hydrochloride (unii: 2s068b75zu) (fexofenadine - unii:e6582loh6v), pseudoephedrine hydrochloride (unii: 6v9v2ryj8n) (pseudoephedrine - unii:7cuc9ddi9f) - fexofenadine hydrochloride 180 mg - allegra-d 24 hour extended-release tablets are indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children 12 years of age and older. symptoms treated effectively include sneezing, rhinorrhea, itchy nose/palate/ and/or throat, itchy/watery/red eyes, and nasal congestion. allegra-d 24 hour should be administered when both the antihistaminic properties of fexofenadine hydrochloride and the nasal decongestant properties of pseudoephedrine hydrochloride are desired (see clinical pharmacology). allegra-d 24 hour is contraindicated in patients with known hypersensitivity to any of its ingredients. due to its pseudoephedrine component, allegra-d 24 hour is contraindicated in patients with narrow-angle glaucoma or urinary retention, and in patients receiving monoamine oxidase (mao) inhibitor therapy or within fourteen (14) days of stopping such treatment (see drug interactions section). it is also contraindicated in patients with severe hypertension, or severe co

ALLEGRA--D 24 HOUR- fexofenadine hydrochloride and pseudoephedrine hydrochloride tablet, film coated, extended release USA - engelsk - NLM (National Library of Medicine)

allegra--d 24 hour- fexofenadine hydrochloride and pseudoephedrine hydrochloride tablet, film coated, extended release

physicians total care, inc. - fexofenadine hydrochloride (unii: 2s068b75zu) (fexofenadine - unii:e6582loh6v), pseudoephedrine hydrochloride (unii: 6v9v2ryj8n) (pseudoephedrine - unii:7cuc9ddi9f) - fexofenadine hydrochloride 180 mg - allegra-d 24 hour extended-release tablets are indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children 12 years of age and older. symptoms treated effectively include sneezing, rhinorrhea, itchy nose/palate/ and/or throat, itchy/watery/red eyes, and nasal congestion. allegra-d 24 hour should be administered when both the antihistaminic properties of fexofenadine hydrochloride and the nasal decongestant properties of pseudoephedrine hydrochloride are desired (see clinical pharmacology). allegra-d 24 hour is contraindicated in patients with known hypersensitivity to any of its ingredients. due to its pseudoephedrine component, allegra-d 24 hour is contraindicated in patients with narrow-angle glaucoma or urinary retention, and in patients receiving monoamine oxidase (mao) inhibitor therapy or within fourteen (14) days of stopping such treatment (see drug interactions section). it is also contraindicated in patients with severe hypertension, or severe coronary arter

Allegra Nasal 55 µg/dose susp. pulv. nas. pompe dos. Belgia - fransk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

allegra nasal 55 µg/dose susp. pulv. nas. pompe dos.

opella healthcare belgium sa-nv - acétonide de triamcinolone 0,055 g/100 g - suspension pour pulvérisation nasale - 55 µg/dose - acétonide de triamcinolone 0.55 mg/g - triamcinolone

Fexallegra 120 mg compresse rivestite con film Italia - italiensk - myHealthbox

fexallegra 120 mg compresse rivestite con film

sanofi s.p.a. - fexofenadina - compresse rivestite con film - 120 mg - antistaminici per uso sistemico - fexallegra è indicato negli adulti e nei bambini a partire dai 12 anni di età per il trattamento sintomatico della rinite allergica stagionale.

ALLEGRA 120 mg Romania - rumensk - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

allegra 120 mg

sanofi winthrop industrie - franta - fexofenadinum - compr. film. - 120mg - antihistaminice de uz sistemic alte antihistaminice de uz sistemic